Magdalena Scheck

Magdalena Scheck

Auto-generated profile, based on publicly available information

Magdalena Scheck

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, 81675 Munich, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
JHJohanna E Huber
Johanna E Huber
JAJulia Ahlfeld
Julia Ahlfeld
MSMagdalena K Scheck
Magdalena K Scheck
MZMagdalena Zaucha
Magdalena Zaucha
KWKlaus Witter
Klaus Witter
DBDirk Baumjohann
Dirk Baumjohann
Objectives: T follicular helper (Tfh) cells are the principal T helper cell subset that provides help to B cells for potent antibody responses against various pathogens. In this study, we took advantage of the live‐attenuated yellow fever virus (YFV) vaccine strain, YF‐17D, as a model system for studying human antiviral immune responses in vivo following exposure to an acute primary virus challenge under safe and highly controlled conditions, to comprehensively analyse the dynamics of circulating Tfh (cTfh) cells.Methods: We tracked and analysed the response of cTfh and other T and B cell subsets in peripheral blood of healthy volunteers by flow cytometry over the course of 4 weeks after YF‐17D vaccination.Results: Using surface staining of cell activation markers to track YFV‐specific T cells, we found increasing cTfh cell frequencies starting at day 3 and peaking around 2 weeks after YF‐17D vaccination. This kinetic was confirmed in a subgroup of donors using MHC multimer staining for four known MHC class II epitopes of YF‐17D. The subset composition of cTfh cells changed dynamically during the course of the immune response and was dominated by the cTfh1‐polarised subpopulation. Importantly, frequencies of cTfh1 cells correlated with the strength of the neutralising antibody response, whereas frequencies of cTfh17 cells were inversely correlated.Conclusion: In summary, we describe detailed cTfh kinetics during YF‐17D vaccination. Our results suggest that cTfh expansion and polarisation can serve as a prognostic marker for vaccine success. These insights may be leveraged in the future to improve current vaccine design and strategies.

29 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MSMagdalena K. Scheck
Magdalena K. Scheck
RHRalf D. Hofheinz
Ralf D. Hofheinz
SLSylvie Lorenzen
Sylvie Lorenzen
Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.

2 September 2025 in Onkologische Welt
Verified
Journal Article
Closed access
PDF file
MSMagdalena Scheck
Magdalena Scheck
SLSylvie Lorenzen
Sylvie Lorenzen
Zusammenfassung: Magenkarzinome sind in Deutschland bei Frauen für 2,3 % und bei Männern für 3,5 % der Krebsneuerkrankungen verantwortlich und gehen mit einer hohen Letalitätsrate einher 1. In der Therapie wird zwischen einer lokalen und einer metastasierten Tumorerkrankung unterschieden. Neue Behandlungsverfahren wie Immuntherapie und zielgerichtete Therapie halten in beiden Fällen Einzug in die derzeitigen Therapiestrategien und verbessern damit die Prognose der Patienten.

13 September 2023 in Gastroenterologie up2date
Verified
Journal Article
Closed access
PDF file
MSMagdalena Scheck
Magdalena Scheck
SLSylvie Lorenzen
Sylvie Lorenzen
Magenkarzinome sind in Deutschland bei Frauen für 2,4% und bei Männern für 3,5% der Krebsneuerkrankungen verantwortlich und gehen mit einer hohen Letalitätsrate einher. In der Therapie unterscheidet man zwischen einer lokalen und einer metastasierten Tumorerkrankung. Neue Verfahren wie Immuntherapie und zielgerichtete Therapie halten in beiden Fällen Einzug in die derzeitigen Therapiestrategien und verbessern die Prognose der Patient*innen. Article published online: 13 September 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

27 March 2024 in TumorDiagnostik & Therapie
Verified
Journal Article
Closed access
PDF file
MSMagdalena Scheck
Magdalena Scheck
SLSylvie Lorenzen
Sylvie Lorenzen
Magenkarzinome sind in Deutschland bei Frauen für 2,4% und bei Männern für 3,5% der Krebsneuerkrankungen verantwortlich und gehen mit einer hohen Letalitätsrate einher. In der Therapie wird zwischen einer lokalen und einer metastasierten Tumorerkrankung unterschieden. Neue Behandlungsverfahren wie Immuntherapie und zielgerichtete Therapie halten in beiden Fällen Einzug in die derzeitigen Therapiestrategien und verbessern damit die Prognose der Patient*innen. Article published online: 27 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

9 October 2025 in bioRxiv
Verified
Preprint
Open access
MZMagdalena Zaucha
Magdalena Zaucha
EWElena Winheim
Elena Winheim
ASAntonio Santos-Peral
Antonio Santos-Peral
ADApurva Dhavale
Apurva Dhavale
PSPaul Schwarzlmueller
Paul Schwarzlmueller
AKAnne B. Krug
Anne B. Krug
The live-attenuated yellow fever vaccine 17D-204 (YF17D) activates robust innate immune responses followed by rapid induction of adaptive immunity resulting in long-lasting protection. YF17D triggers the production of type I interferons (IFNs) which have a dual role in antigen presenting cells regulating their infection and contributing to their activation. Infection with YF17D was detected in primary human blood monocytes and conventional dendritic cells (DCs) and in monocyte-derived DCs but was highly restricted by type I IFN. Blocking IFNAR signaling in YF17D-infected PBMC from vaccinated donors resulted in increased activation of YF17D-specific CD8 + T cells. Consistently, peak IFN-alpha plasma levels correlated inversely with the CD8 + T cells response in YF17D vaccinees. Loss of function experiments demonstrated a dominant role of retinoic acid inducible gene I (RIG-I)-like receptors (RLRs) and mitochondrial antiviral signaling protein (MAVS) for type I IFN induction and restriction of YF17D. The type I IFN response was mediated by 5’ tri- or diphosphate dsRNA intermediates that are formed during YF17D infection. In vivo proximity labelling (IPL) of RIG-I and next-generation sequencing confirmed interaction of RIG-I with YF17D-dsRNA in infected cells. Thus, YF17D-triggered RLR-signaling restricts viral replication through type I IFN and thus limits the production of viral antigens that can be presented to T cells.